颅内动脉瘤的预防性筛查  

Preventive Screening of Intracranial Aneurysm

作　　者：王睿 廖可立[1] 陈贵军[1] 余舟[1] 罗永川 黄颂 张国乐 刘畅 WANG Rui;LIAO Keli;CHEN Guijun;YU Zhou;LUO Yongchuan;HUANG Song;ZHANG Guole;LIU Chang(Zigong First People's Hospital,Sichuan Province,Zigong 643000,China;不详)

机构地区：[1]四川省自贡市第一人民医院,四川自贡643000

出　　处：《中国医学创新》2023年第27期185-188,共4页Medical Innovation of China

摘　　要：颅内动脉瘤(IA)破裂出血是造成致命性脑损伤的主要原因之一,筛查是IA在未破裂之前被发现的唯一办法。最新的研究显示至少有一个直系亲属患有动脉瘤性蛛网膜下腔出血(ASAH)、常染色体显性遗传多囊肾病(ADPKD)、≥35岁的吸烟者或/和高血压的患者是IA筛查的受益群体,但对这一群体进行筛查的频率、成本效益等方面仍存在一些争议。筛查之前应详尽告知患者筛查的利弊,以便患者做出决定。对于存在高危因素的患者,建议尽早启动筛查流程,并且首选CTA或MRA。Ruptured intracranial aneurysm bleeding is one of the leading causes of fatal brain injury and screening is the only way for IA to be detected before it ruptures.Recent studies have shown that people with at least one immediate family member with an aneurysmal subarachnoid haemorrhage(ASAH),people with autosomal dominant polycystic kidney disease(ADPKD),and smokers≥35 years old or/and patients with hypertension are the beneficiaries of screening for IA,but there are still some controversy about the frequency and cost-effectiveness of screening in this group.Patients should be thoroughly informed of the advantages and disadvantages of screening prior to screening so that they can make a decision.For patients with high risk factors,it is recommended to initiate the screening process as soon as possible and prioritize CTA or MRA.

关 键 词：颅内动脉瘤 家族性遗传 预防性治疗 

分 类 号：R743[医药卫生—神经病学与精神病学]